Press Releases Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Delayed Swiss Exchange Other stock markets 03:00:15 2024-07-12 am EDT			5-day change	1st Jan Change
40.6 ^CHF	-1.34%		+2.27%	+15.01%

Jun. 20	Basilea Pharmaceutica to Sell Brain Cancer Drug Candidate to US-based Nonprofit	MT
Jun. 20	Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Basilea Pharmaceutica : Updated June 28, 2024	Jun. 28	PU
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation	Jun. 20	GL
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	May. 16	GL
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024	May. 03	GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	Apr. 24	GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	Apr. 24	AQ
Actym Therapeutics Appoints Thomas Smart as CEO	Apr. 24	PR
Basilea Pharmaceutica : Updated April 9, 2024	Apr. 09	PU
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics	Apr. 09	GL
Basilea Pharmaceutica : Updated April 4, 2024	Apr. 04	PU
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications	Apr. 04	GL
Basilea Pharmaceutica : Updated April 3, 2024	Apr. 03	PU
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	Mar. 11	GL
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	Mar. 11	AQ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	Feb. 13	GL
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	Feb. 13	DJ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	Feb. 13	AQ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea	Jan. 19	GL
Cresemba(R) sales in Latin America trigger first sales milestone payment to Basilea	Jan. 19	DJ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea	Jan. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Press Releases

Filters